

- | | |
|-------------------------|--|
| 1. Record Nr. | UNISA990002203670203316 |
| Autore | LALANDE, Andrè |
| Titolo | Lecture sulla filosofia delle scienze / Andrea Lalande ; tradotte da Carlo Fumagalli |
| Pubbl/distr/stampa | Milano : Albrighi, 1901 |
| Descrizione fisica | VII, 343 p. ; 19 cm |
| Disciplina | 501 |
| Soggetti | Filosofia - Rapporti [con la] Scienza |
| Collocazione | XV.2.A. 2275 |
| Lingua di pubblicazione | Italiano |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
-
- | | |
|-------------------------|---|
| 2. Record Nr. | UNINA9910830042603321 |
| Titolo | Oligonucleotide-based drugs and therapeutics : preclinical and clinical considerations for development // edited by Nicolay Ferrari, Rosanne Seguin |
| Pubbl/distr/stampa | John Wiley & Sons, Inc |
| ISBN | 1-119-07030-9
1-119-07029-5
1-119-07015-5 |
| Disciplina | 572.8/5 |
| Soggetti | Oligonucleotides - Therapeutic use
Antisense nucleic acids - Therapeutic use |
| Lingua di pubblicazione | Inglese |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |

Mechanisms of oligonucleotide actions -- The medicinal chemistry of antisense oligonucleotides -- Cellular pharmacology of antisense oligonucleotides -- Pharmacokinetics and pharmacodynamics of antisense oligonucleotides -- Tissue distribution, metabolism and clearance -- Hybridization-independent effects : principles and specific considerations for oligonucleotide drugs -- Hybridization-dependent effects : the prediction, evaluation and consequences of unintended target hybridization -- Class-related proinflammatory effects -- Exaggerated pharmacology -- Genotoxicity tests for novel oligonucleotide-based therapeutics -- Reproductive and developmental toxicity testing strategies for oligonucleotide-based therapeutics -- Specific considerations for preclinical development of inhaled oligonucleotides -- Lessons learned in oncology programs -- Inhaled antisense for treatment of respiratory disease -- Antisense oligonucleotides for treatment of neurology diseases -- Nucleic acids as adjuvants -- Splice-switching oligonucleotides -- CMC aspects for the clinical development of siRNA.
